The Current Outlook on Cannabis IPO, with Robert Jappie
Robert Jappie is a lawyer and partner at Ince Gordon Dadds LLP, specialising in Life Sciences and Cannabis Regulation
Research and Development: Why is this so important for a cannabis company?
Research and Development plays an important role in the success of any cannabis company.The main goal of R&D
Why Pre-IPO Investments Make Sense: Cannabis Stock Prices Soar Post Flotation
The “Green Rush” is fast becoming an investor’s favourite when capitalising on high-risk opportunities and the demand for
Why Investors Should Love Reverse Take Overs/Mergers
First of all, let’s describe what a reverse takeover is, somewhat similar to the reverse merger, and reverse
Our ESG initiatives to date, and what’s to come
ESG (environmental, social, governance) means an evaluation of a company’s overall impact and conscious attitude toward social and
Medicinal Cannabis: We Don’t Supply a ‘One Size Fits All’
How We Ensure Quality As a cannabis company our goal is to facilitate the global demand’s individual needs
Lyphe Group Part II: Jonathan Nadler talks post-Brexit supply chain and reducing prescription costs
Brexit has impacted the nation in many ways as we have quickly learned. However the disruption for patients
We Talk Medicinal Cannabis Access & Mental Health with Jonathan Nadler, MD of Lyphe Group
Jonathan Nadler is the group Managing Director at Lyphe Group, a UK leader in the supply of medicinal
Rare Skin Conditions: Can Medicinal Cannabis Really Help?
In this blog we are uncovering the effects of rare skin conditions and featuring success stories from using